Absci gained on animal testing phaseout news, but the change has limited near-term impact on its investment case. Read why ...

Absci Corporation’s ABSI share price has surged by 5.86%, which has investors questioning if this is right time to sell.

Absci Corp. research and ratings by Barron's. View ABSI revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Absci Corporation stock has dropped since January, driven by weak earnings and broader biotech sector pressures. Despite weak financials, Absci's internal pipeline, including ABS-101 and ABS-201 ...

Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates ...

KeyBanc raised the firm’s price target on Absci (ABSI) to $9 from $5 and keeps an Overweight rating on the shares. Into Q1 earnings, the firm believes the focus for the HCIT sector will be on ...

Shares of NASDAQ ABSI opened at $3.09 on Wednesday. Absci has a 52 week low of $2.01 and a 52 week high of $6.33. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to ...

7 analysts have expressed a variety of opinions on Absci ABSI over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ...

In a report released today, Scott Schoenhaus from KeyBanc maintained a Buy rating on AbSci (ABSI – Research Report), with a price target of ...

VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report ...

Washington’s life sciences industry injected a $41.2-billion impact into the state’s economy in 2023 — a 6.2% gain over 2022 ...